Havemeyer Place LP Takes $1.04 Million Position in DaVita Inc. $DVA

Havemeyer Place LP acquired a new stake in shares of DaVita Inc. (NYSE:DVA) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 9,118 shares of the company’s stock, valued at approximately $1,036,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of DaVita by 63.5% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 86,000 shares of the company’s stock valued at $9,770,000 after purchasing an additional 33,394 shares during the last quarter. Pinebridge Investments LLC purchased a new stake in shares of DaVita during the 4th quarter valued at $10,363,000. PBU The Pension Fund of Early Childhood & Youth Educators purchased a new stake in shares of DaVita during the 4th quarter valued at $7,210,000. Parallel Advisors LLC lifted its holdings in shares of DaVita by 49.2% during the 4th quarter. Parallel Advisors LLC now owns 670 shares of the company’s stock valued at $76,000 after purchasing an additional 221 shares during the last quarter. Finally, State of Wyoming increased its position in shares of DaVita by 17.7% in the 4th quarter. State of Wyoming now owns 3,447 shares of the company’s stock valued at $392,000 after acquiring an additional 519 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on DVA. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Truist Financial upped their target price on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research report on Friday, May 8th. UBS Group upped their target price on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and upped their target price for the company from $126.00 to $220.00 in a research report on Wednesday, May 6th. Finally, Barclays upped their target price on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $199.17.

Insider Buying and Selling at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares in the company, valued at approximately $25,440,571.40. This trade represents a 27.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.50% of the company’s stock.

DaVita Stock Performance

NYSE DVA opened at $192.28 on Monday. The stock has a 50-day simple moving average of $171.47 and a two-hundred day simple moving average of $143.36. The firm has a market capitalization of $12.34 billion, a P/E ratio of 17.84, a PEG ratio of 0.63 and a beta of 0.91. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $202.69.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. The business had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company’s revenue was up 6.0% on a year-over-year basis. During the same quarter last year, the business posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts forecast that DaVita Inc. will post 15.07 earnings per share for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.